Yahoo! FinanceHome - Yahoo! - Help

Market Guide

[ Stock Screener | Company & Fund Index | Financial Glossary ]

Profile - Salix Pharmaceuticals Ltd (NasdaqNM:SLXP)
As of 31-Aug-2001
Enter symbol:
symbol lookup

 
More Info: Quote | Chart | News | Profile | Research | SEC | Msgs | Insider | Financials
Location
8540 Colonnade Center Drive, Suite 501
Raleigh, NC 27615
Phone: (919) 862-1000
Fax: (919) 862-1095
Email: investor.relations@salixpharm.com
Employees (last reported count): 55
Financial Links
 ·Top Institutional Holders
 ·Top Mutual Fund Holders
 ·Analyst Upgrade/Downgrade History
 ·Historical Quote Data
 ·Raw SEC Filings at sec.gov
Competitors:
 ·Sector: Healthcare
 ·Industry: Biotechnology & Drugs
Company Website
 ·Home Page

 ·Search Yahoo! for related links...

Ownership
·Insider and 5%+ Owners: 32%
·Over the last 6 months:
 · one insider buy; 5,000  shares
 · 5 insider sells; 523.0K shares
  (9.0% of insider shares)
·Institutional: 28% (41% of float)
(59 institutions)
·Net Inst. Buying: 3.48M shares (+42.62%)
(prior quarter to latest quarter)
More From Market Guide
 ·Highlights
 ·Performance
 ·Ratio Comparisons
Business Summary
Salix Pharmaceuticals, Ltd. is a market-driven specialty pharmaceutical company focused on the needs of physicians specializing in gastroenterology. The Company's strategy is to identify and acquire products that have near-term commercial potential, and apply its regulatory, product development and sales and marketing expertise to commercialize these products. The Company selects products to serve a gastrointestinal disease in need of new treatments, and have the potential for rapid regulatory approval. The Company's first two products are balsalazide disodium, which is marketed in the United States under the brand name Colazal, and in the United Kingdom, Sweden and Denmark under the brand names Colazide, Colazid and Premid, respectively, and rifaximin, which is under development.
More from Market Guide: Expanded Business Description

Financial Summary
Salix Pharmaceuticals, Ltd. develops and markets prescription pharmaceutical products for the treatment of gastrointestinal diseases. For the six months ended 6/30/01, revenues totalled $10.7 million, up from $1.7 million. Net loss totalled $7.2 million, up from $2.1 million. Revenues benefitted from sales of COLAZAL(TM). Higher loss reflects increased selling, general and administrative expenses related to the launch of COLAZAL(TM) in the United States.
More from Market Guide: Significant Developments

Officers[Insider Trade Data]
FY2000 Compensation
PayExer

Randy Hamilton, 46
Chairman
$227K$89K
Robert Ruscher, 40
Pres, CEO, Director
244K158K
Adam Derbyshire, 35
CFO, VP of Fin. and Admin., Sec.
--  --  
Carolyn Logan, 52
Sr. VP of Sales and Marketing
--  --  
Lorin Johnson, Ph.D., 48
Sr. VP, Devel. and CSO
186K72K
Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year.
More from Market Guide on Officers & Directors:
Expanded List, Bios, Compensation, Options
Statistics at a Glance -- NasdaqNM:SLXPAs of 31-Aug-2001
Price and Volume
52-Week Low
on 29-Nov-2000
$5.75 
Recent Price$14.80 
52-Week High
on 5-June-2001
$25.23 
Daily Volume (3-month avg)298.9K
Daily Volume (10-day avg)81.0K
Stock Performance
[one-year price graph]
big chart [1d | 5d | 3m | 6m | 1y]
26-Week Change+23.3%
26-Week Change
relative to S&P500
+34.3%
Share-Related Items
Market Capitalization$245.8M
Shares Outstanding16.6M
Float11.3M
Dividends & Splits
Annual Dividendnone 
Last Splitnone 
Per-Share Data
Book Value (mrq)$2.25 
Earnings (ttm)-$0.52 
Earnings (mrq)-$0.22 
Sales (ttm)$1.58 
Cash (mrq)$2.08 
Valuation Ratios
Price/Book (mrq)6.57 
Price/EarningsN/A 
Price/Sales (ttm)9.39 
Income Statements
Sales (ttm)$22.7M
EBITDA (ttm)-$5.90M
Income available to common (ttm)-$7.44M
Profitability
Profit Margin (ttm)-32.8%
Operating Margin (ttm)-26.6%
Fiscal Year
Fiscal Year EndsDec 31
Most recent quarter30-June-2001
Management Effectiveness
Return on Assets (ttm)-27.73%
Return on Equity (ttm)-46.69%
Financial Strength
Current Ratio (mrq)3.94 
Debt/Equity (mrq)0 
Total Cash (mrq)$34.4M
Short Interest
As of 8-Aug-2001
Shares Short316.0K
Percent of Float2.8%
Shares Short
(Prior Month)
180.0K
Short Ratio0.73 
Daily Volume431.0K
See Profile Help for a description of each item above;   K = thousands;   M = millions;   mrq = most-recent quarter;   ttm = trailing twelve months;   (as of 30-June-2001)

Market Guide offers more in-depth Company Research, Stock Screening, and Hottest Stocks and Industries on over 10,000 U.S. Equities.


Copyright © 2001 Yahoo! Inc. All Rights Reserved. Privacy Policy - Terms of Service
Company information Copyright Market Guide. Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Market Guide, CSI, etc.) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.